# Dr Reddy’s gets Brazil approval for generic semaglutide injection 2026-11-05T06:58:19+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 4 independent outlets Dr Reddy’s Laboratories has received marketing authorisation from Brazil’s ANVISA for its generic semaglutide injection, the company said on 5 November. The drug, a generic version of Novo Nordisk’s Ozempic, will be available as a pre-filled, multi-dose injectable pen in 2 mg and 4 mg doses for once-weekly use in adults with insufficiently controlled type 2 diabetes. Brazil has 16.6 million adults aged 20 to 79 living with diabetes, ranking sixth globally, and the semaglutide market there is estimated at about $244.6 million. MV Ramana, CEO of Global Generics at Dr Reddy’s, said the company plans to launch the product in Brazil with partner Aché, adding that the approval builds on its broader semaglutide strategy. Business Standard notes that ANVISA had denied the application in April 2026, and that Dr Reddy’s had recalled a batch of the drug in Canada earlier this year and plans a relaunch there in the current quarter. ## Indian Opinion Analysis All four outlets, CNBC TV18, The Economic Times, The Hindu Business Line, and Business Standard, report the ANVISA approval as a standard corporate disclosure from Dr Reddy’s, with near-identical facts: the two-dose presentation, the $244.6 million market estimate, and the partnership with Aché. The only framing difference comes from Business Standard, which adds two pieces of context the others omit: that ANVISA had earlier denied the application in April 2026, and that Dr Reddy’s had recalled a batch of generic semaglutide in Canada earlier this year and plans a relaunch in the current quarter. While the other outlets treat the approval as a fresh positive step, Business Standard implicitly reminds readers of the regulatory and quality setbacks the company has faced. ## Coverage Coverage: 4 sources, 4 neutral - cnbctv18.com (neutral report) Straight corporate disclosure, no slant - economictimes.indiatimes.com (neutral report) Straight corporate disclosure, no slant - thehindubusinessline.com (neutral report) Straight corporate disclosure, no slant - business-standard.com (neutral report) Adds earlier denial and recall context This brief was synthesised by AI from the 4 sources linked above, so one read covers every framing they carry. Update, 5 November 2026: this story now draws on 4 sources. Last updated 2026-11-05T07:21:10+00:00. Tags: Aché, ANVISA, Brazil, Dr Reddy's Laboratories, semaglutide Canonical: https://indianopinion.org/dr-reddys-gets-brazil-anvisa-approval-for-generic-semaglutide/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/dr-reddys-gets-brazil-anvisa-approval-for-generic-semaglutide/#story-in-brief How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/